Imaging of Atherosclerosis With 68Ga-MSA
Information source: Korea University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atherosclerosis; Noninvasive Imaging of Atherosclerosis
Phase: N/A
Status: Completed
Sponsored by: Korea University
Summary
Despite of intensive efforts, no specific ath¬erosclerosis-targeting agent labeled with
positron emitter is not yet available. Fortunately, some scientists made the major advance
in the field of clinical atherosclerosis molecular imaging by the metabolic PET reporter
agent 18F(fluorine-18)-FDG(Fludeoxyglucose) applied to noninvasively image plaque
macrophages in carotid arteries. However, coronary and cerebral arterial segments remain
uninterpretable due to metabolic property of 18F-FDG. Applying the character of the terminal
mannose residues of MSA binding with the mannose receptors of macrophages in
atherosclerosis, we investigate whether 68Ga-MSA can be a novel agent for non-invasive
molecular imaging of atherosclerotic lesion in PET.
Clinical Details
Official title: Identification of Vascular Inflammatory Image Using a 68Ga-MSA(Gallium-68 Neomannosyl Human Serum Albumin) in Patients With Atherosclerotic Lesions
Study design: Observational Model: Case Control, Time Perspective: Prospective
Primary outcome: comparison of SUV(standard uptake unit) at atherosclerotic plaque of aorta and carotid arteries among 3 groups
Secondary outcome: side effect of PET imaging with 68Ga-MSA
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- acute coronary syndrome(acute myocardial infarction, unstable angina)
- chronic stable angina
- control without coronary artery disease
Exclusion Criteria:
- pregnancy, allergy to albumin, chronic inflammatory disease
Locations and Contacts
Korea University Guro Hospital, Seoul 152-703, Korea, Republic of
Additional Information
Starting date: August 2012
Last updated: August 23, 2013
|